Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AZN is sued by ARRY over cancer drug royalties
https://www.reuters.com/article/us-astrazeneca-array-biopharma/astrazeneca-is-sued-by-array-biopharma-over-cancer-drug-royalties-idUSKBN1FL6O6
“Moderna is now valued at $7.5 billion — and that pumped-up valuation could make a future IPO that much more difficult.
@damiangarde reports:”
https://twitter.com/rebeccadrobbins/status/959141688613789698
I suppose they will eventually need to seek a Stemcentrx-like buyout.
https://www.fiercebiotech.com/abbvie-bags-a-unicorn-9-8b-buyout-deal-for-stemcentrx
“I’m the ideal person to support right to try. But I can’t — it’s a disaster in the making”
https://www.statnews.com/2018/02/01/right-to-try-cancer-fda/
About the author: “Michael D. Becker is president and founder of MDB Communications LLC. He previously served as president, chief operating officer, chief financial officer, and director for several publicly traded biotechnology companies, including Cytogen, VioQuest Pharmaceuticals, and Relmada Therapeutics.”
Novo Nordisk got beat out on one of the first big healthcare deals of the year — here's what the CEO is still looking for in an acquisition
http://www.businessinsider.com/novo-nordisk-ceo-on-acquisition-targets-in-biotech-2018-2
Cancer ‘vaccine’ eliminates tumors in mice
http://med.stanford.edu/news/all-news/2018/01/cancer-vaccine-eliminates-tumors-in-mice.html?linkId=47615873
—Activating T cells in tumors eliminated even distant metastases in mice, Stanford researchers found. Lymphoma patients are being recruited to test the technique in a clinical trial.
The Jeff Bezos Empire In One Giant Chart
https://www.zerohedge.com/news/2018-01-28/visualizing-jeff-bezos-empire-one-giant-chart
Question is, who is(are) the buyer(s)? 13G(s) should be filed in coming days IMO.
Cancer immunotherapy beyond immune checkpoint inhibitors
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0552-6
#5 january
Breaking: Neurodegeneration star Denali nabs a cash-rich, $1B-plus #Alzheimers partnership with Takeda
$DNLI
#5 january
— John Carroll (@JohnCendpts) January 31, 2018
Breaking: Neurodegeneration star Denali nabs a cash-rich, $1B-plus #Alzheimers partnership with Takeda$DNLIhttps://t.co/m0qnihX8Rf
SGEN to Acquire CASC, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline
https://www.businesswire.com/news/home/20180131005494/en/Seattle-Genetics-Acquire-Cascadian-Therapeutics-Adding-Late-Stage
Jeff Bezos and his two friends just spooked healthcare stocks
http://money.cnn.com/2018/01/30/investing/health-care-stocks-jpmorgan-chase-amazon-berkshire-hathaway/index.html
Pfizer sweeps out a lineup of neurosciences drugs — as well as cancer and NASH programs — into the scrap heap
https://endpts.com/pfizer-sweeps-out-a-lineup-of-neurosciences-drugs-as-well-as-cancer-and-nash-programs-into-the-scrap-heap/
The Boston Cancer Summit & Seattle Cancer Summit. Two Can’t-Miss Events
https://timmermanreport.com/2018/01/boston-cancer-summit-seattle-cancer-summit-two-cant-miss-events/
Novo Nordisk remains on hunt for biopharma deals
https://www.reuters.com/article/us-ablynx-m-a-sanofi-novo-nordisk/novo-nordisk-remains-on-hunt-for-biopharma-deals-idUSKBN1FI1J0
[OT]The Startling Link Between Sugar and Alzheimer's
—A high-carb diet, and the attendant high blood sugar, are associated with cognitive decline.
https://www.theatlantic.com/health/archive/2018/01/the-startling-link-between-sugar-and-alzheimers/551528/
Behind the deal spree, Celgene continues to cautiously explore neurosciences
https://endpts.com/behind-the-deal-spree-celgene-continues-to-cautiously-explore-neurosciences/
Is SAGE next?
Saudi Aramco will list in Hong Kong eventually, says the city's stock exchange chief
https://www.cnbc.com/2018/01/24/hong-kong-exchanges-and-clearing-ceo-on-saudi-aramco-chinese-investors.html
—Access to Chinese investors will eventually bring Saudi Aramco to list in Hong Kong, said Charles Li, CEO of Hong Kong Exchanges and Clearing
—Hong Kong is competing against New York and London for what is expected to be the world's largest IPO ever
—A win for Hong Kong would be a welcomed boost for the city that recently lost its crown as the global IPO leader
Bioverativ—SEC files suit over possible insider trading
https://uk.reuters.com/article/us-bioverativ-insidertrading-sec/u-s-sec-files-suit-over-possible-insider-trading-on-bioverativ-idUKKBN1FG02M
[OT]Canadian pharmaceutical billionaire couple was murdered: police
https://www.reuters.com/article/us-canada-death-apotex/canadian-pharmaceutical-billionaire-couple-was-murdered-police-idUSKBN1FF2G2
(Apotex Pharma, TEVA)
Celgene Says Juno, Impact Deals Won't Be Its Last
https://www.thestreet.com/story/14463223/1/celgene-not-done-making-deals.html
VKTX +17%. 52wk high hit today. (eom)
Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
https://endpts.com/novartis-scores-a-quick-fda-ok-for-its-new-cancer-drug-lutathera-picked-up-in-4b-buyout/
Jennison Associates LLC ups stake to 2.69M shares from 1.6M shares.
https://whalewisdom.com/stock/mrns-2
Fast-growing Chinese pharma to plant foot in San Diego, hunting deals in US and Europe
https://endpts.com/fast-growing-chinese-pharma-to-plant-foot-in-san-diego-hunting-deals-in-us-and-europe/
Biogen buys a brain disorder drug for $217 million, but needs to go bigger, analyst says
https://www.cnbc.com/2018/01/25/biogen-buys-brain-drug-for-217-million-but-must-go-bigger-analyst.html
Biotech Deals Are Costly. So Are In-House Clinical Failures
https://www.bloomberg.com/news/articles/2018-01-25/biotech-deals-are-costly-so-are-in-house-clinical-failures
Women’s health biotech KaNDy dickering with Allergan about a $400M buyout deal
https://endpts.com/womens-health-biotech-kandy-dickering-with-allergan-about-a-400m-buyout-deal-report/
Celgene's Investments Are Soaring—The biotech Goliath's investment portfolio is paying off.
https://www.fool.com/investing/2018/01/23/celgenes-investments-are-soaring.aspx
Drugmakers ‘flush with cash’ and hunting for deals
https://www.ft.com/content/85711950-0088-11e8-9650-9c0ad2d7c5b5
I think it’s the latter. If you see the web article, it has a report link for each ticker. I removed them here before I posted. No reasoning behind why these stocks are relevant for this article by the “author”.
NVS—Why This Heart Drug Could Be a $5B Blockbuster
https://www.biospace.com/article/around-the-web/why-this-heart-drug-could-be-a-5b-blockbuster-for-novartis/
These Are the 20 Best Stocks to Own as Millennials Take Over the Stock Market
https://www.thestreet.com/story/14447696/1/these-are-the-20-best-stocks-to-own-as-millennials-take-over-the-equities-market.html
NIH to launch genome editing research program
https://www.nih.gov/news-events/news-releases/nih-launch-genome-editing-research-program
You are right. I don’t have free FT articles remaining for this month so not sure what their basis for the statement is.
Big Pharma makes the strongest start to M&A for a decade
Big Pharma makes strongest start to M&A for a decade https://t.co/OmYKOn0NOm
— Financial Times (@FT) January 22, 2018
Biotech's $20 Billion Merger Monday Results May Disappoint
https://www.bloomberg.com/gadfly/articles/2018-01-22/celgene-juno-sanofi-bioverativ-deals-may-disappoint
MRNS' Ganaxolone: If At First You Don't Succeed...
https://seekingalpha.com/article/4139020-marinus-pharmas-ganaxolone-first-succeed
Prudential Financial buys 6.7% stake in MRNS (eom)
Prudential Financial buys 6.7% stake in MRNS (eom)